NVG-291
NVG-291 is an investigational peptide drug candidate developed by NervGen Pharma Corp. and is being studied primarily for its potential role in neural repair and functional recovery following nervous system injury. NVG-291 is a peptide-based compound designed to target Protein Tyrosine Phosphatase Sigma (PTPσ), with research focused on modulating inhibitory signaling associated with the post-injury neural environment.
PTPσ has been implicated in mechanisms that restrict axonal regeneration and neural repair following injury. By targeting PTPσ, NVG-291 is designed to modulate these inhibitory pathways and potentially promote processes associated with axonal regeneration, restoration of neural connectivity, and functional recovery.
NVG-291 is currently being investigated as a novel neural repair candidate, with potential research applications in areas including spinal cord injury, central nervous system injury, and other conditions involving neural damage. Its pharmacological effects, clinical efficacy, and safety profile remain subject to ongoing scientific and clinical evaluation.
Product Information:
- Name: NVG-291
- Developer: NervGen Pharma Corp.
- Type: Investigational peptide drug candidate
- Primary Target: Protein Tyrosine Phosphatase Sigma (PTPσ)
- Research Focus: Neural repair, axonal regeneration, and functional recovery
- Potential Research Areas: Spinal cord injury, central nervous system injury, and other neural injury-related conditions
- Development Status: Under clinical investigation; not an approved marketed drug
Research Use Only
